SAGE Stock Cash Flow Statements

Sage Therapeutics Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Sage Therapeutics Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30

cash flows from operating activities
net income	-62,214,000	-95,778,000	-93,551,000	-102,854,000	-108,483,000	-32,706,000	-201,630,000	-160,325,000	-146,828,000	-147,146,000	-137,323,000	-126,260,000	-122,055,000	-124,712,000	-130,171,000	-107,245,000	-95,764,000	974,895,000	-105,735,000	-136,347,000	-126,740,000	-168,653,000	-179,958,000	-168,221,000	-163,406,000	-158,388,000	-122,918,000	-16,978,000	-74,598,000	-69,422,000	-73,719,000	-70,201,000	-56,778,000	-55,901,000	-37,796,000	-34,747,000	-30,543,000	-28,562,000	-24,035,000	-25,027,000	-16,871,000	-12,361,000	-9,468,000
adjustments to reconcile net income to net cash from operating activities:
stock-based compensation expense	6,927,000	9,432,000	14,207,000	17,167,000	13,698,000	12,945,000	28,691,000	11,693,000	20,038,000	15,244,000	13,169,000	14,636,000	18,553,000	20,648,000	34,342,000	27,663,000	21,976,000	20,744,000	20,108,000	24,032,000	31,110,000	30,679,000	43,669,000	34,767,000	44,116,000	31,640,000	25,478,000	29,028,000	15,817,000	10,245,000	9,731,000	9,350,000	6,208,000	10,093,000	4,748,000	4,465,000	3,714,000	4,086,000	4,407,000	5,398,000	1,349,000	1,326,000	691,000
premium on marketable securities	-137,000	-158,000	-51,000	-112,000	-23,000	-61,000	0	-42,000	-29,000	-36,000	-10,000	-265,000	-1,189,000	-3,849,000	-2,919,000	-7,414,000	-9,459,000	-670,000	-572,000	-254,000	-240,000	-1,022,000	-765,000	-1,148,000	-739,000	-50,000	-90,000	-71,000	-4,000	-56,000				-93,000	-394,000
amortization of discount on marketable securities	-981,000		-2,047,000	-1,937,000	-1,554,000																-18,000	-537,000	-1,456,000	-2,651,000	-2,322,000
depreciation expense	112,000	129,000	255,000	311,000	336,000	409,000	330,000	331,000	323,000	290,000	278,000
changes in operating assets and liabilities:
prepaid expenses and other current assets	-2,144,000	1,881,000	9,113,000	-2,155,000	5,237,000	2,880,000	11,616,000	12,529,000	-8,024,000	2,191,000	-11,562,000	-4,249,000	2,635,000	-5,498,000	-5,497,000	-5,763,000	-262,000	7,526,000	-1,485,000	-3,383,000	1,221,000	3,713,000	-3,392,000	-6,739,000	1,637,000	-3,191,000	12,820,000	-19,743,000	-5,348,000	-1,335,000	301,000	1,287,000	-1,380,000	-1,682,000	-1,606,000	1,115,000	-1,189,000	867,000	671,000	-2,085,000	-134,000	7,000	-287,000
collaboration receivable - related party	-1,595,000	5,737,000	-4,928,000	566,000	72,500,000	-60,496,000	-7,423,000	-88,000	-1,342,000	4,788,000	5,274,000	-3,925,000	-1,291,000	5,679,000	24,253,000	-23,672,000	-24,766,000
other long-term assets	220,000	847,000	2,625,000	-84,000	332,000	45,000	296,000	-2,634,000	515,000	139,000	-2,000	-316,000	-340,000	-376,000	-276,000	-207,000	-51,000	86,000	-12,000	279,000	99,000	25,000	205,000	-2,645,000	-1,378,000
right-of-use operating asset	396,000	623,000	1,441,000	1,637,000	1,601,000	1,568,000	1,534,000	1,502,000	1,470,000	1,438,000	1,409,000	1,380,000	1,350,000	1,323,000	1,296,000	1,269,000	1,333,000	1,483,000	1,453,000	1,683,000	1,778,000	1,744,000
operating lease liabilities, current	494,000	1,235,000	-1,328,000	-1,895,000	-1,859,000	-1,802,000	-758,000	41,000	41,000	40,000	40,000	40,000	55,000	54,000	55,000	53,000	44,000	42,000	43,000	-74,000	25,000
operating lease liabilities, non-current	-475,000	-1,228,000				0	-1,003,000	-1,760,000	-1,728,000	-1,673,000	-1,636,000	-1,596,000	-1,568,000	-1,517,000	-1,482,000	-1,447,000	-1,498,000	-1,631,000	-1,592,000	-1,705,000	-1,897,000
accounts payable	-7,264,000	5,573,000	-1,524,000	2,171,000	-3,839,000	-818,000	1,889,000	-3,016,000	-6,550,000	11,790,000	1,868,000	-1,974,000	-3,251,000	5,647,000	1,816,000	-368,000	-406,000	-598,000	1,902,000	-5,508,000	-7,307,000	10,172,000	-7,149,000	-1,299,000	-20,507,000	27,914,000	-2,467,000	-26,000	-877,000	-3,914,000	6,989,000	-2,125,000	-4,643,000	7,680,000	-825,000	1,740,000	-799,000	1,882,000	-1,952,000	2,417,000	343,000	447,000	379,000
accrued expenses and other liabilities	-15,067,000	6,090,000	-6,726,000	6,748,000	-15,778,000	-47,664,000	35,543,000	14,642,000	-8,389,000	-12,668,000	8,562,000	13,230,000	-4,507,000	443,000	5,349,000	10,106,000	-4,140,000	8,025,000	-6,100,000	1,309,000	-35,391,000	8,312,000	19,522,000	14,162,000	-8,192,000	2,925,000	9,450,000	10,215,000	-12,460,000	5,684,000	10,581,000	2,511,000	1,220,000	5,846,000	4,920,000	937,000	1,341,000	3,743,000
net cash from operating activities	-81,728,000	-66,560,000	-82,365,000	-80,437,000	-37,832,000	-119,519,000	-135,866,000	-131,518,000	-153,682,000	-126,932,000	-118,865,000	-106,439,000	-107,800,000	-97,501,000	-68,826,000	-102,769,000	-109,086,000	1,010,971,000	-91,016,000	-118,984,000	-136,691,000	-116,726,000	-128,702,000	-133,344,000	-149,934,000	-101,778,000	-80,187,000	-135,000	-78,571,000	-58,899,000	-46,092,000	-59,076,000	-55,210,000	-33,776,000	-30,796,000	-26,671,000	-27,435,000	-18,117,000	-19,515,000	-18,443,000	-14,606,000	-8,667,000	-7,486,000
capex	0	0	0	0	0	112,000	-328,000	-112,000	-225,000	-199,000	-566,000	-122,000	-169,000	0	0	0	0	0	1,000	-70,000	-261,000	-319,000	-2,181,000	-2,007,000	-1,179,000	-776,000	-989,000	-407,000	-637,000	508,000	-235,000	-76,000	-181,000	-520,000	-66,000	0	-62,000	-38,000	21,000	-71,000	-110,000	-45,000	-78,000
free cash flows	-81,728,000	-66,560,000	-82,365,000	-80,437,000	-37,832,000	-119,407,000	-136,194,000	-131,630,000	-153,907,000	-127,131,000	-119,431,000	-106,561,000	-107,969,000	-97,501,000	-68,826,000	-102,769,000	-109,086,000	1,010,971,000	-91,015,000	-119,054,000	-136,952,000	-117,045,000	-130,883,000	-135,351,000	-151,113,000	-102,554,000	-81,176,000	-542,000	-79,208,000	-58,391,000	-46,327,000	-59,152,000	-55,391,000	-34,296,000	-30,862,000	-26,671,000	-27,497,000	-18,155,000	-19,494,000	-18,514,000	-14,716,000	-8,712,000	-7,564,000
cash flows from investing activities
proceeds from sales and maturities of marketable securities	133,756,000	135,278,000	183,371,000	197,932,000	201,054,000	176,905,000	230,779,000	278,470,000	351,982,000	288,591,000	362,716,000	263,561,000	292,539,000	288,863,000	338,273,000	177,969,000	182,970,000	135,410,000	170,570,000	320,572,000	275,197,000	213,430,000	369,188,000	281,389,000	307,263,000	250,625,000	460,672,000	181,500,000	81,960,000	46,789,000	104,000,000	59,683,000	50,753,000
purchases of marketable securities	-87,973,000	-88,704,000	-102,317,000	-198,318,000	-61,618,000	-134,956,000	-70,059,000	-232,765,000	-156,890,000	-198,532,000	-251,400,000	-129,177,000	-301,928,000	-318,752,000	-363,256,000	-466,357,000	-841,786,000	-89,891,000	-157,058,000	-143,120,000	-68,651,000	-230,973,000	-159,469,000	-337,317,000	-580,916,000	-211,399,000	-459,622,000	-419,228,000	-394,109,000	-150,587,000	-59,894,000	-15,014,000	-18,908,000	-140,443,000	-35,653,000
net cash from investing activities	45,783,000	46,574,000	81,054,000	-386,000	139,436,000	42,061,000	160,392,000	45,593,000	194,867,000	89,777,000	110,952,000	134,262,000	-9,558,000	-30,261,000	-24,983,000	-288,388,000	-658,816,000	45,519,000	13,513,000	177,382,000	206,270,000	-17,916,000	207,779,000	-58,109,000	-274,910,000	38,418,000	52,000	-238,130,000	-312,801,000	-104,602,000	43,871,000	44,308,000	31,600,000	-118,463,000	-27,720,000	-84,016,000	-341,000	-38,000	21,000	-71,000	-110,000	-45,000	-78,000
cash flows from financing activities
proceeds from stock option exercises and employee stock purchase plan issuances	242,000	-1,000	1,435,000	26,000	1,559,000	0	2,774,000	855,000	3,301,000	33,000	1,244,000	37,000	1,799,000	419,000	1,816,000	6,861,000	5,623,000	2,171,000	3,545,000	386,000	3,160,000	2,166,000	15,402,000	15,601,000	15,681,000	1,628,000	8,078,000	6,645,000	12,757,000	8,974,000	3,687,000	2,758,000	553,000	678,000	416,000	10,000	302,000
payment of employee tax obligations related to vesting of restricted stock units	-94,000	-1,000	-399,000	-1,000	-2,000	-262,000	-4,000	-8,000	-629,000	-4,000	-15,000			-589,000	0							0	-1,483,000	0	-692,000	0	0	0	-904,000
net cash from financing activities	148,000	-2,000	1,037,000	8,071,000	1,557,000	-262,000	2,770,000	847,000	2,672,000	29,000	1,229,000	13,000	1,799,000	-170,000	1,816,000	6,065,000	5,623,000	419,671,000	3,545,000	386,000	3,160,000	2,166,000	13,919,000	15,343,000	576,196,000	1,628,000	8,078,000	6,540,000	643,112,000	334,820,000	3,687,000	2,758,000	553,000	678,000	189,591,000	10,000	140,703,000	31,000	137,000	129,586,000	112,000	-249,000	95,164,000
net increase in cash, cash equivalents and restricted cash	-35,797,000	-19,988,000	-274,000	-72,752,000	103,161,000				43,857,000					-127,932,000	-91,993,000	-385,092,000	-762,279,000	1,476,161,000	-73,958,000	58,784,000	72,739,000	-132,476,000	92,996,000	-176,110,000	151,352,000			-231,725,000	251,740,000
cash, cash equivalents, and restricted cash at beginning of period	82,471,000
cash, cash equivalents, and restricted cash at end of period	46,674,000
reconciliation of cash, cash equivalents, and restricted cash reported in the consolidated balance sheets
cash and cash equivalents	45,224,000
restricted cash	1,450,000
total cash, cash equivalents, and restricted cash shown in the statement of cash flows	46,674,000
amortization of (discount) premium on marketable securities
purchases of property and equipment						112,000	-328,000	-112,000	-225,000	-282,000	-364,000	-122,000	-169,000					0	1,000	-70,000	-276,000	-373,000	-1,940,000	-2,181,000	-1,257,000	-808,000	-998,000	-402,000	-652,000	-804,000	-235,000	-76,000	-245,000	-520,000	-66,000
payments of offering costs		0	0																			0	0	-258,000	-70,000	0	0	-105,000	-235,000					0	0
proceeds from public offerings of common stock, net of commissions and underwriting discounts		0	1,000																			0	0	0	561,277,000	0	0	0	631,494,000					0	189,175,000
supplemental disclosure of non-cash operating activities
right-of-use assets obtained in exchange for new operating lease liabilities		125,000																				0
purchases of property and equipment included in accounts payable										83,000	-202,000										15,000	54,000	-241,000	174,000	78,000	32,000	9,000	-5,000	15,000
cash, cash equivalents and restricted cash at beginning of period			0	0	72,324,000	0	0	0	163,969,000	0	0	0	295,502,000	0	0	0	1,662,798,000	0	0	0	129,072,000	0	0	0	193,310,000	0	0	0	307,084,000
cash, cash equivalents and restricted cash at end of period			-274,000	-72,752,000	175,485,000	-77,720,000	27,296,000	-85,078,000	207,826,000	-37,126,000	-6,684,000	27,836,000	179,943,000	-127,932,000	-91,993,000	-385,092,000	900,519,000	1,476,161,000	-73,958,000	58,784,000	201,811,000	-132,476,000	92,996,000	-176,110,000	344,662,000	-61,732,000	-72,057,000	-231,725,000	558,824,000
amortization of premium (discount) on marketable securities						6,181,000	-4,951,000	-4,391,000	-3,179,000								1,325,000	420,000	324,000									-2,806,000	-1,348,000
net decrease in cash, cash equivalents and restricted cash						-77,720,000	27,296,000				-6,684,000	27,836,000	-115,559,000
lease asset de-recognized upon lease cancellation														0	0	0	3,733,000	0	0
adjustments to reconcile net income to net cash (used in) operating activities:
amortization of premium on marketable securities										-1,329,000	1,068,000	2,581,000	3,533,000		4,034,000																-62,000	-28,000	33,000	199,000	74,000
proceeds from the sale of common stock under the stock purchase agreement - related party
supplemental disclosure of non-cash operating and investing activities
depreciation													275,000	333,000	374,000	893,000	2,582,000	649,000	650,000	662,000	669,000	665,000	698,000	505,000	415,000	363,000	287,000	246,000	247,000	135,000	136,000	130,000	130,000	82,000	83,000	75,000	41,000	32,000
proceeds from the sale of common stock under the stock purchase agreement
landlord tenant incentive included in other current assets
public offering costs included in accounts payable
purchases of property and equipment financed with landlord tenant incentive																														1,312,000
operating lease liabilities																							-1,787,000	-1,846,000	-2,500,000
right of use operating asset																								1,771,000	2,942,000
right of use assets obtained in exchange for new operating lease liabilities
supplemental disclosure of non-cash investing and financing activities
public offering costs included in accrued expenses																									259,000				105,000
supplemental disclosure of non-cash operating, investing and financing activities
supplemental disclosure of non-cash investing activities
non-cash licensing and consulting fees																																						0	0	787,000	424,000
increase in restricted cash																														0	0			0	0
net increase in cash and cash equivalents																														171,319,000	1,466,000	-12,010,000	-23,057,000	-151,561,000	131,075,000	-110,677,000	112,927,000	-18,124,000	-19,357,000	111,072,000	-14,604,000	-8,961,000	87,600,000
cash and cash equivalents at beginning of period																														0	0	0	168,517,000	0	0	0	186,753,000	0	0	0	127,766,000	0	0
cash and cash equivalents at end of period																														171,319,000	1,466,000	-12,010,000	145,460,000	-151,561,000	131,075,000	-110,677,000	299,680,000	-18,124,000	-19,357,000	111,072,000	113,162,000	-8,961,000	87,600,000
supplemental disclosure of non-cash financing activities
public offering costs included in accounts payable or accrued expenses																																						161,000	-133,000
purchases of property and equipment included in accounts payable or accrued expenses																																	64,000				279,000
proceeds from the issuance of series b preferred stock, net of issuance costs																																										0	0
proceeds from the issuance of series c preferred stock, net of issuance costs																																										0	0
accretion of redeemable convertible preferred stock to redemption value																																										0	391,000
conversion of preferred stock to common stock
proceeds from sales of marketable securities
purchase of property and equipment																																					-341,000	-38,000	21,000	-71,000	-110,000	-45,000	-78,000
payment of offering costs																																					-599,000	-36,000	-90,000	-423,000	-35,000	-250,000	-1,128,000
proceeds from public offering of common stock, net of commissions and underwriting discounts																																					141,000,000	0	0
deferred offering costs
proceeds from the issuance of series a preferred stock, net of issuance costs
proceeds from stock option exercise and employee stock purchase plan issuances
depreciation and amortization																																								32,000	22,000	16,000	13,000
accrued expenses and other																																								35,000	261,000		1,186,000
proceeds from stock option exercises and restricted stock
proceeds from the issuance of common stock and restricted stock																																									147,000	1,000	37,000
deferred public offering costs included in accounts payable or accrued expenses																																									151,000
licensing or consulting fees paid in common stock																																										0	0
accrued expenses
other liabilities
proceeds from initial public offering of common stock, net of commissions and underwriting discounts																																										0
conversion of redeemable convertible preferred stock to common stock
changes in operating assets and liabilities
proceeds from convertible notes payable
initial public offering costs included in accounts payable or accrued expenses
deferred initial public offering costs included in accounts payable or accrued expenses

We provide you with 20 years of cash flow statements for Sage Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Sage Therapeutics stock. Explore the full financial landscape of Sage Therapeutics stock with our expertly curated income statements.

The information provided in this report about Sage Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.